A randomized phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomas.
Completed
- Conditions
- Epithelial ovarian cancer, ovarian fallopian tube or primary peritoneal carcinomas
- Registration Number
- NL-OMON25042
- Lead Sponsor
- VU medical center
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
1. Histologically confirmed epithelial ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer;
2. Age ¡Ý 18 year;
Exclusion Criteria
1. ECOG performance status > 2.
2. Prior treatment with chemotherapy or radiotherapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate, progression-free survival.
- Secondary Outcome Measures
Name Time Method Safety, overall survival, tolerability.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does COX-2 inhibition with celecoxib enhance docetaxel and carboplatin efficacy in stage IC-IV epithelial ovarian carcinomas?
What is the comparative progression-free survival of celecoxib plus docetaxel/carboplatin versus standard chemotherapy in advanced ovarian cancer?
Which biomarkers correlate with response to celecoxib in combination with docetaxel and carboplatin for stage IC-IV ovarian carcinomas?
What are the safety profiles and adverse event management strategies for celecoxib combined with docetaxel and carboplatin in ovarian cancer patients?
How do other COX-2 inhibitors compare to celecoxib in combination with docetaxel and carboplatin for treating advanced ovarian carcinomas?